20 completed, 5 recruiting, 4 terminated, 4 unknown. 16 Phase 2, 14 Phase 1, 5 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Non Small Cell Lung Cancer (NSCLC): new trials by email Literature Review of Non Small Cell Lung Cancer (NSCLC) trials Research Report on Non Small Cell Lung Cancer (NSCLC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer JSKN033 Injection - Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 160 | 2025-12-10 | 2025-12-15 |
| Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer LS301-IT 0.1 mg/kg - Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Integro Theranostics | 35 | 2025-12-08 | 2026-04-20 |
| Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis Blood sample collection - Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer) | Not yet recruiting | OncoHost Ltd. | 600 | 2025-11-15 | 2025-11-24 | |
| A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC Osimertinib (Tagrisso®), WSD0922-FU - Non Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Wayshine Biopharm, Inc. | 48 | 2025-10-17 | 2025-11-28 |
| Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer Non Small Cell Lung Cancer, Non Small Cell Lung Cancer (NSCLC) | Recruiting | Barzilai Medical Center | 10 | 2025-01-20 | 2026-10-15 | |
| Liquid BiOpsy, Lung and Colon Cancer in AndaluciA xF Tempus assay - Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Enrolling by invitation | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | 500 | 2024-08-01 | 2025-05-30 | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Darlifarnib, Cabozantinib, Adagrasib - Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Kura Oncology, Inc. | 300 | 2023-10-18 | 2026-10-14 |
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies AP203 - Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | AP Biosciences Inc. | 168 | 2023-07-24 | 2025-03-26 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies AB308, Zimberelimab - Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | Arcus Biosciences, Inc. | 94 | 2021-03-19 | 2025-08-28 |
| Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors ABBV-637, Docetaxel, Osimertinib - Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Active not recruiting | AbbVie | 81 | 2021-02-23 | 2025-07-03 |
| Osimertinib Study in Indian Patients Osimertinib - Non Small Cell Lung Cancer (NSCLC) | Phase 4 | Completed | AstraZeneca | 60 | 2019-04-18 | 2021-06-03 |
| Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. Pembrolizumab - Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 65 | 2018-05-23 | 2021-06-09 |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors Enapotamab vedotin (HuMax-AXL-ADC) - Ovarian Cancer, Cervical Cancer | Phase 1 / Phase 2 | Completed | Genmab | 306 | 2016-11-23 | 2023-08-01 |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Radiotherapy, MEDI4736, Tremelimumab - Metastatic, Melanoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 53 | 2016-01-26 | 2025-11-25 |
| Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases cabozantinib - Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain | Phase 2 | Terminated | Liza Villaruz, MD | 5 | 2015-12-01 | 2021-03-10 |
| Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM Vinorelbine - Non Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma (MPM) | Phase 1 | Completed | Assistance Publique Hopitaux De Marseille | 30 | 2015-08-26 | 2022-11-17 |
| Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT FLT-PET - Non Small Cell Lung Cancer (NSCLC) | Not applicable | Completed | University Health Network, Toronto | 45 | 2015-05-01 | 2023-03-22 |
| A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Nivolumab - Non Small Cell Lung Cancer (NSCLC) | Phase 3 | Completed | Bristol-Myers Squibb | 1428 | 2014-04-09 | 2022-10-27 |
| Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom SABR is Considered Non Small Cell Lung Cancer (NSCLC), Intrathoracic Nodal Staging | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 102 | 2013-12-01 | 2016-12-20 | |
| Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) Pembrolizumab, Docetaxel - Non Small Cell Lung Cancer (NSCLC) | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 1034 | 2013-08-09 | 2021-10-06 |
Showing 20 of 38. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (38) · Lung Neoplasms (6) · Melanoma (4) · Colorectal Neoplasms (3) · Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Kidney Neoplasms (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Uterine Cervical Neoplasms (2) · Breast Diseases (1) · Bronchial Neoplasms (1)
Bronchial Neoplasms (37) · Carcinoma, Bronchogenic (37) · Lung Diseases (37) · Neoplasms by Site (37) · Respiratory Tract Diseases (37) · Respiratory Tract Neoplasms (37) · Thoracic Neoplasms (37) · Neoplasms (35) · Lung Neoplasms (32) · Neoplasms by Histologic Type (10) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms, Glandular and Epithelial (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6)
Docetaxel (5) · Cetuximab (3) · osimertinib (3) · Erlotinib Hydrochloride (2) · Gefitinib (2) · Vinorelbine (2) · cabozantinib (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Calcitriol (1) · Cisplatin (1) · DNA (1) · Doxycycline (1) · Nitroglycerin (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · AstraZeneca (2) · Maastricht Radiation Oncology (2) · UNC Lineberger Comprehensive Cancer Center (2) · AP Biosciences Inc. (1) · AbbVie (1) · Abramson Cancer Center at Penn Medicine (1) · Arcus Biosciences, Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Barzilai Medical Center (1) · Bristol-Myers Squibb (1) · Cascadian Therapeutics Inc. (1) · Fatebenefratelli and Ophthalmic Hospital (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental (1)
United States (18) · Spain (8) · Netherlands (6) · Italy (5) · Belgium (4) · Canada (4) · France (4) · South Korea (4) · Taiwan (4) · Australia (3) · Germany (3) · Poland (3) · Argentina (2) · Austria (2) · Brazil (2)
Alberto Scanni, MD (1) · Athanassios Argiris, MD (1) · Dirk De Ruysscher, MD, PhD (1) · Harry Drabkin, MD (1) · Harry Groen, MD, PhD (1) · Howard A Burris, M.D. (1) · Ignace Vergote, Professor (1) · Jared Weiss, MD (1) · Jouke T Annema, MD PhD (1) · Jouke T Annema, MD, PhD (1) · Juneko Grilley Olson, MD (1) · Liza Villaruz, MD (1)
PMID 26712084, PMID 10704469, PMID 11698646, PMID 11784875, PMID 11910893, PMID 12091876, PMID 12218188, PMID 12538684, PMID 12695859, PMID 14756433, PMID 15598424, PMID 15771580, PMID 15800326, PMID 16271509, PMID 17167137, PMID 17195077, PMID 17360651, PMID 17363529, PMID 17404099, PMID 17577038, PMID 17602225, PMID 17717638, PMID 17928188, PMID 18486758, PMID 18506025, PMID 18565862, PMID 18698686, PMID 18705415, PMID 18791714, PMID 18941457, PMID 19013709, PMID 19021626, PMID 19188168, PMID 19188680, PMID 19338264, PMID 19380770, PMID 19410716, PMID 19519321, PMID 19656725, PMID 19717085, PMID 19720422, PMID 19908042, PMID 20005150, PMID 20087581, PMID 20143437, PMID 20221835, PMID 20231618, PMID 20477813, PMID 20482675, PMID 20516428
2016 (1)